Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

The US Food and Drug Administration approved the first GLP-1 in 2005, for treatment of type 2 diabetes. In the past few years, the agency has approved several GLP-1s for obesity after patients ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Ozempic is approved by the U.S. Food and Drug Administration to treat Type 2 ... is FDA-approved for weight loss in people with obesity or who are overweight with additional risks for ...